Pharvaris to Showcase Key Clinical Data at AAAAI 2026
Event summary
- Pharvaris accepted six abstracts for poster presentations at the AAAAI 2026 Annual Meeting, including three in the Featured Poster session.
- Presentations will cover topline RAPIDe-3 data, final CHAPTER-1 study results, and pharmacokinetic data of deucrictibant extended-release tablet.
- Topline data from the pivotal CHAPTER-3 study is anticipated in Q3 2026.
- Posters and presentation slides will be available on Pharvaris' Investors section during the event.
The big picture
Pharvaris is positioning itself as a key player in the treatment of bradykinin-mediated diseases, particularly hereditary angioedema (HAE). The upcoming presentations at AAAAI 2026 are critical for validating its clinical data ahead of the anticipated CHAPTER-3 topline results. The company aims to set a new standard of care with its oral bradykinin B2 receptor antagonists, challenging existing injectable treatments.
What we're watching
- Clinical Validation
- How the presentation of RAPIDe-3 and CHAPTER-1 data will be received by the medical community and investors.
- Regulatory Pathway
- The pace at which Pharvaris advances global marketing authorization applications based on the upcoming CHAPTER-3 topline data.
- Competitive Positioning
- Whether Pharvaris can differentiate deucrictibant's efficacy and convenience in the bradykinin-mediated angioedema market.
Related topics